At the J.P. Morgan Healthcare Conference, Boston Scientific forecast that pulsed field ablation will be used in more than 60% of atrial fibrillation procedures globally by 2026.

Sean Salmon, who leads the company’s cardiovascular group, said cryoablation procedures draw the company less revenue per case than PFA procedures. Medtronic’s adjusted net profit rose to $1. ...

After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued ...

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins. See ...

Cryoablation and radiofrequency ablation ... Victor Stefanescu covers medical technology startups and large companies such as Medtronic for the business section. He reports on new inventions ...

Just months after FDA approval, Johnson & Johnson paused the rollout of its Varipulse pulsed field ablation (PFA) platform in ...

Let's take a closer look at whether Medtronic's dividend is safe and if you can comfortably rely on its payout for the foreseeable future. Medtronic's payout ratio is well over 80% A stock's ...

Medtronic remains a "Buy" due to its undervalued stock, recent product launches, and resolved supply chain issues, despite underperformance over the past 7 months. The company posted solid Q2 ...

Looking at the universe of stocks we cover at Dividend Channel, on 12/27/24, Medtronic PLC (Symbol: MDT), DENTSPLY SIRONA Inc (Symbol: XRAY), and Danaher Corp (Symbol: DHR) will all trade ex ...

The FDA is elevating a recall from Boston Scientific covering its cryoablation balloon catheters for the treatment of atrial fibrillation. No hardware is being removed from use—instead, ...